Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034916.xml
Download PDF
Nervenheilkunde 2005; 24(09): 801-808
DOI: 10.1055/s-0038-1630011
DOI: 10.1055/s-0038-1630011
Original Article
Frontotemporale lobäre Degenerationen
Frontotemporal lobar degenerationsFurther Information
Publication History
Eingegangen am:
17 May 2005
angenommen am:
21 June 2005
Publication Date:
24 January 2018 (online)
Zusammenfassung
Die frontotemporalen lobären Degenerationen (FTLD) stellen die Ursache unterschiedlicher und vielfältiger psychiatrischer und neurologischer Störungen dar. In der vorliegenden Übersichtsarbeit werden die einzelnen klinischen Syndrome vorgestellt, die genetischen und pathologischen Grundlagen erläutert, die derzeitigen Möglichkeiten der Diagnostik vorgestellt und Therapieoptionen aufgezeigt.
Summary
Frontotemporal degenerations cause various clinical psychiatric and neurological syndromes. This review introduces the clinical syndromes, genetic basis and pathological variability, diagnostic procedures and therapeutic strategies.
-
Literatur
- 1 Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration, frontotemporal dementia, progressive aphasia and semantic dementia. London: Churchill Livingstone; 1996
- 2 Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002; 58: 1615-21.
- 3 Boeve B, Lang A, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54 (Suppl. 05) S15-9.
- 4 Hodges JR. Frontotemporal dementia (Pick’s disease): Clinical features and assessment. Neurology 2001; 56 (Suppl. 04) S6-10.
- 5 The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57: 416-8.
- 6 Neary D. et al. Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-54.
- 7 Pasquier F, Richard F, Lebert F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17: 355-9.
- 8 Diehl J, Grimmer T, Krapp S, Foerstl H, Lautenschlager N, Kurz A. Results of a 1 year follow-up study of patients with frontotemporal dementia (FTD) and semantic dementia (SD): Clinical decline and cognitive impairment much more progressive in FTD than in SD. Neurobiology of Aging 2004; 25 (Suppl. 02) 452.
- 9 Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol 1982; 11: 592-8.
- 10 Mesulam M. Primary progressive aphasia. Ann Neurol 2001; 49: 425-32.
- 11 Cappa SF, Peranie D, Messa C, Miozzo A, Fazio F. Varieties of progressive non-fluent aphasia. Ann NY Acad Sci 1996; 770: 243-8.
- 12 Mesulam M. Primary progressive aphasia – a language-based dementia. N Engl J Med 2003; 349: 1535-42.
- 13 Sonty S. et al. Primary progressive aphasia: PPA and the language network. Ann Neurol 2003; 53: 35-49.
- 14 Kertesz A, Lage-Martinez P, Davidson W. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000; 55: 1368-75.
- 15 Galton C, Patterson K, Xuereb J, Hodges J. Atypical and typical presentations of Alzheimer’s disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000; 123: 484-98.
- 16 Garrard P, Hodges J. Semantic dementia: Clinical, radiological and pathological perspectives. J Neurol 2000; 247: 409-22.
- 17 Rosen HJ, Hartikainen KM, Jagust W, Kramer JH, Reed BR, Cummings JL. et al. Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD. Neurology 2002; 58: 1608-15.
- 18 Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortico-basal ganglionic degeneration. Neurology 1999; 53: 1969-74.
- 19 Lang A. Corticobasal degeneration: selected developments. Mov Disord 2003; 18 (Suppl. 06) S51-6.
- 20 Kertesz A, Lage-Martinez P, Davidson W. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000; 55: 1368-75.
- 21 Kertesz A, Munoz D. Relationship between frontotemporal dementia and corticobasal degeneration/progressive supranuclear palsy. Dement Geriatr Cogn Disord 2004; 17: 282-6.
- 22 Steele R, Richardson J, Olszewski J. Progressive supranuklear palsy. Arch Neurol 1964; 10: 333-59.
- 23 Litvan I. et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60: 615-20.
- 24 Grafman J, Litvan I, Gomez C, Chase TN. Frontal lobe function in progressive supranuclear palsy. Arch Neurol 1990; 47: 553-8.
- 25 Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol 1993; 50: 347-79.
- 26 Litvan I. Update on progressive supranuclear palsy. Can J Neurol Neurosci Rep 2004; 4: 296-302.
- 27 Bak TH, Hodges JR. Cognition, language and behaviour in motor neurone disease: Evidence of frontotemporal dysfunction. Dementia Geriatr Cogn Disord 1998; 10 (Suppl. 01) 29-32.
- 28 Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17: 337-41.
- 29 Diehl J, Kurz A. Frontotemporal dementia: patient characteristics, cognition, and behaviour. J Geriatr Psychiatry 2002; 17: 914-8.
- 30 Johnson J. et al. Frontotemporal lobar degeneration: demographic characteristics among 353 patients. Arch Neurol. 2005 in press
- 31 Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology 2003; 349-54.
- 32 Riemenschneider M, Diehl J, Mueller U, Foerstl H, Kurz A. Apolipoprotein E polymorphism in German patients with frontotemporal degeneration. J Neurol Neurosurg Psychiatry 2002; 72: 639-41.
- 33 Chow TW, Miller BL, Hayashi VN, Geschwind DH. Inheritance of frontotemporal dementia. Arch Neurol 1999; 56: 817-22.
- 34 Foster NL, Wilhelmsen K, Sima AAF, Jones MZ, D’Amato CJ, Gilman S. Frontotemporal dementia and Parkinsonism linked to chromosome 17: A consensus conference. Ann Neurol 1997; 41: 706-15.
- 35 Brown J. et al. Familial nonspecific dementia maps to chromosome 3. Hum Mol Genet 1995; 4: 1625-8.
- 36 Hosler BA. et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000; 284: 1664-9.
- 37 Munoz DG, Dickson DW, Bergeron C, McKenzie IRA, Delacourte A, Zhukareva V. The neuropathology and biochemistry of frontotemporal dementia. Ann Neurol 2003; 54 (Suppl. 05) S24-8.
- 38 Neumann M, Kretzschmar H. Pathologie und Biochemie der frontotemporalen Demenzen. Nervenheilkunde 2004; 23: 73-9.
- 39 Jackson M, Lowe J. The new neuropathology of degenerative frontotemporal dementias. Acta Neuropathol 1996; 91: 127-34.
- 40 Josephs K. et al. Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 2004; 30: 369-73.
- 41 Lipton A, White C, Bigio E. Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol 2004; 108: 379-89.
- 42 Cairns N, Grossmann M, Arnold S, Burn D, Jaros E, Perry R. et al. Clinic and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 2004; 63: 1346-84.
- 43 Kertesz A, Nadkarni N, Davidson W, Thomas AW. The Frontal Behavioural Inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc 1999; 6: 460-8.
- 44 Gregory CA. Frontal variant of frontotemporal dementia: a cross-sectional and lognitudinal study of neuropsychiatric features. Psychol Med 1999; 29: 1205-17.
- 45 Rosen H, Pace-Savitsky K, Perry R, Kramer J, Miller B, Levenson R. Recognition of emotion in the frontal and temporal variants of frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17: 277-81.
- 46 Galton C. et al. Temporal lobe rating scale: application to Alzheimer’s disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 2001; 70: 165-73.
- 47 Miller B, Gearhart R. Neuroimaging in the diagnosis of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10 (Suppl. 01) 71-4.
- 48 Garraux C, Salmon E, Degueldre C, Lemaire C, Laureys S, Franck G. Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortico-frontal dementia, and cortical frontal dementia. Neuroimage 1999; 10: 149-62.
- 49 Diehl J, Grimmer T, Drzezga A, Riemenschneider M, Foerstl H, Kurz A. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study. Neurobiol Aging 2004; 25: 1051-6.
- 50 Gorno-Tempini M. et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55: 335-46.
- 51 Chan D, Fox N, Rossor M. Differing pattern of temporal atrophy in Alzheimer’s disease and semantic dementia. Neurology 2002; 12: 838.
- 52 Nagahama Y. et al. Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls. Mov Disord 1997; 12: 691-6.
- 53 Foster NL. et al. Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. J Neurol Neurosurg Psychiatry 1992; 55: 707-13.
- 54 Riemenschneider M. et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002; 58: 1622-8.
- 55 Grossman M. et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol 2005; 57: 721-9.
- 56 Hampel H, Teipel S. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17: 350-4.
- 57 Vanmechelen E. et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49-52.
- 58 Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick’s disease. Arch Neurol 1991; 48: 796-9.
- 59 Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58: 212-6.
- 60 Ikeda M. et al. Efficacy of Fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 2004; 17: 117-21.
- 61 Moretti R, Torre P, Antonello R, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003; 49: 13-9.
- 62 Deakin J, Rahman S, Nestor P, Hodges J, Sahakian B. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 2004; 172: 400-8.
- 63 Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with Trazodone. Dement Geriatr Cogn Disord 2004; 17: 355-9.
- 64 Moretti R, Torre P, Antonello R, Cazzato G, Bava A. Effects of selegiline on frontotemporal dementia: a neuropsychological evaluation. J Geriatr Psychiatry 2002; 17: 391-2.
- 65 Chow T, Miller B, Boone K, Mishkin F, Cummings J. Frontotemporal dementia: Classification and neuropsychiatry. The Neurologist 2002; 8: 263-9.
- 66 Pijnenburg Y, Sampson E, Harvey R, Fox N, Rossor M. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. J Geriatr Psychiatry 2003; 18: 67-72.